Home・Lista de Ações・Iovance Biotherapeutics Inc

Iovance Biotherapeutics Inc

Fechado

SetorSaúde

4.37 1.63

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

4.29

Máximo

4.47

Indicadores-chave
By Trading Economics
Rendimento	-7.1M -79M
Vendas	-15M 71M
EPS	-0.19
Margem de lucro	-110.661
Funcionários	975
EBITDA	-3.4M -71M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+126.85% upside

Dividendos
By Acuity
Próximos Ganhos	6 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	208M 1.9B
Abertura anterior	2.74
Fecho anterior	4.37

Sentimento de Notícias

By Acuity

34%

66%

130 / 340 Ranking em Healthcare

Iovance Biotherapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

4 de ago. de 2026, 19:51 UTC

Iovance Biotherapeutics is rising amid broader market strength from falling crude oil prices and positive economic data, despite lingering inflation concerns.

3 de ago. de 2026, 19:51 UTC

Iovance Biotherapeutics shares are higher today, rebounding from an earlier low. The stock has advanced since Friday, amid positive market sentiment.

31 de jul. de 2026, 23:41 UTC

Iovance Biotherapeutics shares are higher in after-market trading, maintaining gains since Friday's close amid broader market volatility following a decline in Apple shares.

30 de jul. de 2026, 23:51 UTC

Iovance Biotherapeutics shares are lower in after-market trading, reflecting ongoing weakness and pulling back from a brief session high earlier.

29 de jul. de 2026, 15:16 UTC

Iovance Biotherapeutics Inc shares are lower today, continuing a trend of declines over the past six sessions with no specific news identified.

28 de jul. de 2026, 23:56 UTC

Iovance Biotherapeutics shares declined in after-market trading, continuing a trend of lower finishes over the past five sessions. No specific news was identified.

27 de jul. de 2026, 19:36 UTC

Social Media

Iovance Biotherapeutics is lower today, continuing a trend of declines over four consecutive trading days. Earlier, shares rebounded from a session low.

24 de jul. de 2026, 19:12 UTC

Iovance Biotherapeutics Inc shares are lower today, continuing a downward trend amid broader market volatility influenced by falling oil prices and geopolitical tensions.

22 de jul. de 2026, 23:11 UTC

Iovance Biotherapeutics shares are higher in after-market trading, supported by gains in the Biotechnology sub-sector. The stock remains near its one-month trading range high.

21 de jul. de 2026, 19:46 UTC

Social Media

Iovance Biotherapeutics shares are higher amid positive social media sentiment and favorable earnings reports from peers, including General Motors and Novartis.

20 de jul. de 2026, 19:16 UTC

Social Media

Iovance Biotherapeutics Inc shares are higher today, with significant trading volume reaching 23.48 million. The stock has fluctuated between 4.44 and 5.07 during the session.

Comparação entre Pares

Variação de preço

Iovance Biotherapeutics Inc Previsão

Preço-alvo

By TipRanks

126.85% parte superior

Previsão para 12 meses

Média 9.8 USD 126.85%

Máximo 14 USD

Mínimo 5 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Iovance Biotherapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

5 ratings

Comprar

Manter

Vender

Com base em 5 analistas que deram avaliações de ações para Iovance Biotherapeutics Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

130 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.